Immune Pharmaceuticals - Company & Market Research Reports

Immune Pharmaceuticals is a clinical stage biopharmaceutical company that develops novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas. The company's lead product candidate is Bertilimumab, a human monoclonal antibody, which is in Phase II clinical trial for the treatment of ulcerative colitis, bullous pemphigoid, and Crohn's disease. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in New York, New York.